Chimerix Inc (NAS:CMRX)
$ 1.05 0.0795 (8.19%) Market Cap: 94.11 Mil Enterprise Value: -71.04 Mil PE Ratio: 0 PB Ratio: 0.54 GF Score: 53/100

Chimerix Inc DSTAT Clinical Update Conference Call Transcript

Apr 29, 2020 / 12:30PM GMT
Release Date Price: $2.15 (+42.38%)
Operator

Good morning, ladies and gentlemen. Please be advised that today's conference is being recorded at Chimerix's request.

I would now like to turn the call over to Michelle LaSpaluto from Chimerix. Please go ahead.

Michelle LaSpaluto
Chimerix, Inc. - VP of Strategic Planning & IR

Thank you. And welcome to the Chimerix DSTAT Clinical Program Update Conference Call.

Earlier this morning, we issued a press release announcing the initiation of a Phase II/III study of dociparstat sodium for the treatment of acute lung injury, or ALI, for patients with severe COVID-19. Also, last evening, we issued a press release announcing the FDA's clearance for a rolling NDA submission of BCV as a countermeasure for smallpox. These press releases are available on the company's website at www.chimerix.com. You may also access today's call via webcast on the Investors section of the Chimerix website. An archive of the webcast will be available approximately 2 hours after the conclusion of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot